Insulin Resistance In Preeclampsia And Its Effect On Maternal-Fetal Outcomes
Öz
Aims
It is controversial whether insulin resistance and hyperinsulinemia in preeclamptic patients are due to weight gain during pregnancy or preeclampsia. This study aims investigation of the relation between insulin resistance and weight gain, obesity, biochemical parameters and fetal outcomes of insulin resistance in pregnant women with mild and severe preeclampsia without gestational diabetes.
Methods
This research was performed in Perinatology Department of Tepecik Training and Research Hospital. Non-diabetic preeclamptic 101 pregnant women between 18-44 years of age in 24-40 gestational weeks were involved in the research. Demographic data, biochemical parameters, weight measurements ,enquiries regarding glucose metabolism and data about fetuses were recorded.Homeostatic Model Assessment (HOMA) value of 2.5 and above and insulin sensitivity index below 6 were evaluated as insulin resistance.
Results
There is no remarkable variation in both groups concerning fasting and postprandial glucose level, HOMA-IR (homeostatic model assessment insulin resistance), insulin sensitivity index. Only, postprandial insulin was significantly higher in severe preeclampsia group (p <0,05). On the other hand, when the effects on fetal outcomes were examined; delivery time, birth weight, and 1 and 5 min apgar scores were significantly worse in the severe preeclampsia group.
Conclusion
Therefore, postprandial insulin levels should be taken into consideration in order to predict the effect of insulin resistance and sensitivity on the prognosis of the disease and maternal -fetal outcomes in preeclampsia cases. The relationship should be studied with large prospective randomised controlled studies to reveal whether it is a useful parameter estimating metabolic syndrome in subsequent years .
Anahtar Kelimeler
Preeclampsia, Insulin Sensitivity, Postprandial Hyperglycemia
Etik Beyan
Declaration of interest statement
Author has no potential conflicts of interest to disclose.
Funding Sources
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Teşekkür
Acknowledgements
I would like to express my deepest appreciation to Assoc. Prof. Dr. Cüneyt Eftal Taner for his guidance and backing for my thesis.
Kaynakça
- 1. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002; 325: 157- 60.
- 2. Akıncı B, Çeltik A, Yener S, Yeflil S. Prediction of developing metabolic syndrome after gestational diabetes mellitus. Fertil Steril 2010; 93: 1248- 54.
- 3. Ehrenthal DB, McNeil RB, Crenshaw EG, Bairey Merz CN, Grobman WA, Parker CB. et al.Adverse Pregnancy Outcomes and Future Metabolic Syndrome. J Womens Health (Larchmt). 2023 Sep;32(9):932-941.
- 4. Costa IM, da Silva TEM, Silva LG, Silva Ferreira AP, Paraguai CMDC, Ferreira CN. et al. Preeclampsia beyond pregnancy: investigating the long-term increase in cardiovascular disease and metabolic syndrome (PERLA- Brazil study). Women Health. 2025 Apr;65(4):328-339.
- 5. Forest JC, Girouard J, Masse J, Moutquin JM, Kharfi A, Ness RB, et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005; 105: 1373-80.
- 6. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002; 325: 157- 60.
- 7. Laivuori H, Tikkanen MJ, Ylikorkala O. Hyperinsulinaemia 17 years after pre-eclamptic first pregnancy. J Clin Endocrinol Metab 1996; 81: 2908- 11.
- 8. Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001; 357: 2002- 6.
- 9. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension 2007; 49: 1056-62.
- 10. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1. doi: 10.1097/AOG.0000000000003018. PMID: 30575675.